Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 18 entries
Sorted by: Best Match Show Resources per page
Asymptomatic Internal Carotid Artery Origin Stenosis.

Current treatment options in cardiovascular medicine

Furie KL, Topcuoglu MA, Kelly PJ, Koroshetz WJ, Kistler JP.
PMID: 11527525
Curr Treat Options Cardiovasc Med. 2001 Oct;3(5):441-447. doi: 10.1007/s11936-001-0033-6.

Proper therapy for patients with internal carotid artery stenosis requires a precise pathophysiologic diagnosis that includes characterization and localization of ischemic disease of the brain and knowledge of the arterial disease and the collateral cerebral circulation. Noninvasive techniques such...

Cite
Furie KL, Topcuoglu MA, Kelly PJ, et al. Asymptomatic Internal Carotid Artery Origin Stenosis. Curr Treat Options Cardiovasc Med. 2001;3(5):441-447doi: 10.1007/s11936-001-0033-6.
Furie, K. L., Topcuoglu, M. A., Kelly, P. J., Koroshetz, W. J., & Kistler, J. P. (2001). Asymptomatic Internal Carotid Artery Origin Stenosis. Current treatment options in cardiovascular medicine, 3(5), 441-447. https://doi.org/10.1007/s11936-001-0033-6
Furie, Karen L., et al. "Asymptomatic Internal Carotid Artery Origin Stenosis." Current treatment options in cardiovascular medicine vol. 3,5 (2001): 441-447. doi: https://doi.org/10.1007/s11936-001-0033-6
Furie KL, Topcuoglu MA, Kelly PJ, Koroshetz WJ, Kistler JP. Asymptomatic Internal Carotid Artery Origin Stenosis. Curr Treat Options Cardiovasc Med. 2001 Oct;3(5):441-447. doi: 10.1007/s11936-001-0033-6. PMID: 11527525.
Copy Download .nbib Format: NLM
Athermal emission in Yb,Er:glass.

Optics express

Koroshetz J, Brickeen B, Fahr S, Rapaport A, Bass M.
PMID: 19547510
Opt Express. 2007 Sep 03;15(18):11530-5. doi: 10.1364/oe.15.011530.

We report on the temperature dependent spectroscopic properties of Yb(3+) and Er(3+) co-doped glass gain media in the eye-safe spectral region. Measurements suggest that judicious selection of the operating wavelength can lead to a laser output with minimal dependence...

Cite
Koroshetz J, Brickeen B, Fahr S, et al. Athermal emission in Yb,Er:glass. Opt Express. 2007;15(18):11530-5doi: 10.1364/oe.15.011530.
Koroshetz, J., Brickeen, B., Fahr, S., Rapaport, A., & Bass, M. (2007). Athermal emission in Yb,Er:glass. Optics express, 15(18), 11530-5. https://doi.org/10.1364/oe.15.011530
Koroshetz, John, et al. "Athermal emission in Yb,Er:glass." Optics express vol. 15,18 (2007): 11530-5. doi: https://doi.org/10.1364/oe.15.011530
Koroshetz J, Brickeen B, Fahr S, Rapaport A, Bass M. Athermal emission in Yb,Er:glass. Opt Express. 2007 Sep 03;15(18):11530-5. doi: 10.1364/oe.15.011530. PMID: 19547510.
Copy Download .nbib Format: NLM
Concussion research at the National Institutes of Health: an update from the National Institute of Neurological Disorders and Stroke.

Concussion (London, England)

Mott M, Koroshetz W.
PMID: 30202554
Concussion. 2015 Oct 26;1(2):CNC10. doi: 10.2217/cnc.15.10. eCollection 2016 Mar.

No abstract available.

Cite
Mott M, Koroshetz W. Concussion research at the National Institutes of Health: an update from the National Institute of Neurological Disorders and Stroke. Concussion. 2015;1(2):CNC10doi: 10.2217/cnc.15.10.
Mott, M., & Koroshetz, W. (2016). Concussion research at the National Institutes of Health: an update from the National Institute of Neurological Disorders and Stroke. Concussion (London, England), 1(2), CNC10. https://doi.org/10.2217/cnc.15.10
Mott, Meghan, and Koroshetz, Walter. "Concussion research at the National Institutes of Health: an update from the National Institute of Neurological Disorders and Stroke." Concussion (London, England) vol. 1,2 (2016): CNC10. doi: https://doi.org/10.2217/cnc.15.10
Mott M, Koroshetz W. Concussion research at the National Institutes of Health: an update from the National Institute of Neurological Disorders and Stroke. Concussion. 2015 Oct 26;1(2):CNC10. doi: 10.2217/cnc.15.10. eCollection 2016 Mar. PMID: 30202554; PMCID: PMC6114014.
Copy Download .nbib Format: NLM
Do process simulations during episodic future thinking enhance the reduction of delay discounting for middle income participants and those living in poverty?.

Journal of behavioral decision making

O'Donnell S, Daniel TO, Koroschetz J, Kilanowski C, Otminski A, Bickel WK, Epstein LH.
PMID: 34334945
J Behav Decis Mak. 2019 Jul;32(3):231-240. doi: 10.1002/bdm.2108. Epub 2018 Oct 31.

Two studies examined whether episodic future thinking (EFT; pre-experiencing future events) reduces discounting of future rewards (DD). No studies have investigated whether process simulations (i.e., simulating the process of executing a future event) amplify EFT's reduction of DD. Study...

Cite
O'Donnell S, Daniel TO, Koroschetz J, et al. Do process simulations during episodic future thinking enhance the reduction of delay discounting for middle income participants and those living in poverty?. J Behav Decis Mak. 2018;32(3):231-240doi: 10.1002/bdm.2108.
O'Donnell, S., Daniel, T. O., Koroschetz, J., Kilanowski, C., Otminski, A., Bickel, W. K., & Epstein, L. H. (2019). Do process simulations during episodic future thinking enhance the reduction of delay discounting for middle income participants and those living in poverty?. Journal of behavioral decision making, 32(3), 231-240. https://doi.org/10.1002/bdm.2108
O'Donnell, Sara, et al. "Do process simulations during episodic future thinking enhance the reduction of delay discounting for middle income participants and those living in poverty?." Journal of behavioral decision making vol. 32,3 (2019): 231-240. doi: https://doi.org/10.1002/bdm.2108
O'Donnell S, Daniel TO, Koroschetz J, Kilanowski C, Otminski A, Bickel WK, Epstein LH. Do process simulations during episodic future thinking enhance the reduction of delay discounting for middle income participants and those living in poverty?. J Behav Decis Mak. 2019 Jul;32(3):231-240. doi: 10.1002/bdm.2108. Epub 2018 Oct 31. PMID: 34334945; PMCID: PMC8323832.
Copy Download .nbib Format: NLM
Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study.

JAMA neurology

, Feigin VL, Vos T, Alahdab F, Amit AML, Bärnighausen TW, Beghi E, Beheshti M, Chavan PP, Criqui MH, Desai R, Dhamminda Dharmaratne S, Dorsey ER, Wilder Eagan A, Elgendy IY, Filip I, Giampaoli S, Giussani G, Hafezi-Nejad N, Hole MK, Ikeda T, Owens Johnson C, Kalani R, Khatab K, Khubchandani J, Kim D, Koroshetz WJ, Krishnamoorthy V, Krishnamurthi RV, Liu X, Lo WD, Logroscino G, Mensah GA, Miller TR, Mohammed S, Mokdad AH, Moradi-Lakeh M, Morrison SD, Shivamurthy VKN, Naghavi M, Nichols E, Norrving B, Odell CM, Pupillo E, Radfar A, Roth GA, Shafieesabet A, Sheikh A, Sheikhbahaei S, Shin JI, Singh JA, Steiner TJ, Stovner LJ, Wallin MT, Weiss J, Wu C, Zunt JR, Adelson JD, Murray CJL.
PMID: 33136137
JAMA Neurol. 2021 Feb 01;78(2):165-176. doi: 10.1001/jamaneurol.2020.4152.

IMPORTANCE: Accurate and up-to-date estimates on incidence, prevalence, mortality, and disability-adjusted life-years (burden) of neurological disorders are the backbone of evidence-based health care planning and resource allocation for these disorders. It appears that no such estimates have been reported...

Cite
, Feigin VL, Vos T, et al. Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study. JAMA Neurol. 2021;78(2):165-176doi: 10.1001/jamaneurol.2020.4152.
, Feigin, V. L., Vos, T., Alahdab, F., Amit, A. M. L., Bärnighausen, T. W., Beghi, E., Beheshti, M., Chavan, P. P., Criqui, M. H., Desai, R., Dhamminda Dharmaratne, S., Dorsey, E. R., Wilder Eagan, A., Elgendy, I. Y., Filip, I., Giampaoli, S., Giussani, G., Hafezi-Nejad, N., Hole, M. K., Ikeda, T., Owens Johnson, C., Kalani, R., Khatab, K., Khubchandani, J., Kim, D., Koroshetz, W. J., Krishnamoorthy, V., Krishnamurthi, R. V., Liu, X., Lo, W. D., Logroscino, G., Mensah, G. A., Miller, T. R., Mohammed, S., Mokdad, A. H., Moradi-Lakeh, M., Morrison, S. D., Shivamurthy, V. K. N., Naghavi, M., Nichols, E., Norrving, B., Odell, C. M., Pupillo, E., Radfar, A., Roth, G. A., Shafieesabet, A., Sheikh, A., Sheikhbahaei, S., Shin, J. I., Singh, J. A., Steiner, T. J., Stovner, L. J., Wallin, M. T., Weiss, J., Wu, C., Zunt, J. R., Adelson, J. D., & Murray, C. J. L. (2021). Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study. JAMA neurology, 78(2), 165-176. https://doi.org/10.1001/jamaneurol.2020.4152
, et al. "Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study." JAMA neurology vol. 78,2 (2021): 165-176. doi: https://doi.org/10.1001/jamaneurol.2020.4152
, Feigin VL, Vos T, Alahdab F, Amit AML, Bärnighausen TW, Beghi E, Beheshti M, Chavan PP, Criqui MH, Desai R, Dhamminda Dharmaratne S, Dorsey ER, Wilder Eagan A, Elgendy IY, Filip I, Giampaoli S, Giussani G, Hafezi-Nejad N, Hole MK, Ikeda T, Owens Johnson C, Kalani R, Khatab K, Khubchandani J, Kim D, Koroshetz WJ, Krishnamoorthy V, Krishnamurthi RV, Liu X, Lo WD, Logroscino G, Mensah GA, Miller TR, Mohammed S, Mokdad AH, Moradi-Lakeh M, Morrison SD, Shivamurthy VKN, Naghavi M, Nichols E, Norrving B, Odell CM, Pupillo E, Radfar A, Roth GA, Shafieesabet A, Sheikh A, Sheikhbahaei S, Shin JI, Singh JA, Steiner TJ, Stovner LJ, Wallin MT, Weiss J, Wu C, Zunt JR, Adelson JD, Murray CJL. Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study. JAMA Neurol. 2021 Feb 01;78(2):165-176. doi: 10.1001/jamaneurol.2020.4152. PMID: 33136137; PMCID: PMC7607495.
Copy Download .nbib Format: NLM
NINDS launches network to develop treatments for ultra-rare neurological diseases.

Nature biotechnology

Schor NF, Tamiz AP, Koroshetz WJ, Broome AM.
PMID: 34737446
Nat Biotechnol. 2021 Nov 04; doi: 10.1038/s41587-021-01125-w. Epub 2021 Nov 04.

No abstract available.

Cite
Schor NF, Tamiz AP, Koroshetz WJ. NINDS launches network to develop treatments for ultra-rare neurological diseases. Nat Biotechnol. 2021;doi: 10.1038/s41587-021-01125-w.
Schor, N. F., Tamiz, A. P., Koroshetz, W. J., & Broome, A. M. (2021). NINDS launches network to develop treatments for ultra-rare neurological diseases. Nature biotechnology, . https://doi.org/10.1038/s41587-021-01125-w
Schor, Nina F, et al. "NINDS launches network to develop treatments for ultra-rare neurological diseases." Nature biotechnology vol. (2021). doi: https://doi.org/10.1038/s41587-021-01125-w
Schor NF, Tamiz AP, Koroshetz WJ, Broome AM. NINDS launches network to develop treatments for ultra-rare neurological diseases. Nat Biotechnol. 2021 Nov 04; doi: 10.1038/s41587-021-01125-w. Epub 2021 Nov 04. PMID: 34737446.
Copy Download .nbib Format: NLM
Current directions in tau research: Highlights from Tau 2020.

Alzheimer's & dementia : the journal of the Alzheimer's Association

Sexton C, Snyder H, Beher D, Boxer AL, Brannelly P, Brion JP, Buée L, Cacace AM, Chételat G, Citron M, DeVos SL, Diaz K, Feldman HH, Frost B, Goate AM, Gold M, Hyman B, Johnson K, Karch CM, Kerwin DR, Koroshetz WJ, Litvan I, Morris HR, Mummery CJ, Mutamba J, Patterson MC, Quiroz YT, Rabinovici GD, Rommel A, Shulman MB, Toledo-Sherman LM, Weninger S, Wildsmith KR, Worley SL, Carrillo MC.
PMID: 34581500
Alzheimers Dement. 2021 Sep 28; doi: 10.1002/alz.12452. Epub 2021 Sep 28.

Studies supporting a strong association between tau deposition and neuronal loss, neurodegeneration, and cognitive decline have heightened the allure of tau and tau-related mechanisms as therapeutic targets. In February 2020, leading tau experts from around the world convened for...

Cite
Sexton C, Snyder H, Beher D, et al. Current directions in tau research: Highlights from Tau 2020. Alzheimers Dement. 2021;doi: 10.1002/alz.12452.
Sexton, C., Snyder, H., Beher, D., Boxer, A. L., Brannelly, P., Brion, J. P., Buée, L., Cacace, A. M., Chételat, G., Citron, M., DeVos, S. L., Diaz, K., Feldman, H. H., Frost, B., Goate, A. M., Gold, M., Hyman, B., Johnson, K., Karch, C. M., Kerwin, D. R., Koroshetz, W. J., Litvan, I., Morris, H. R., Mummery, C. J., Mutamba, J., Patterson, M. C., Quiroz, Y. T., Rabinovici, G. D., Rommel, A., Shulman, M. B., Toledo-Sherman, L. M., Weninger, S., Wildsmith, K. R., Worley, S. L., & Carrillo, M. C. (2021). Current directions in tau research: Highlights from Tau 2020. Alzheimer's & dementia : the journal of the Alzheimer's Association, . https://doi.org/10.1002/alz.12452
Sexton, Claire, et al. "Current directions in tau research: Highlights from Tau 2020." Alzheimer's & dementia : the journal of the Alzheimer's Association vol. (2021). doi: https://doi.org/10.1002/alz.12452
Sexton C, Snyder H, Beher D, Boxer AL, Brannelly P, Brion JP, Buée L, Cacace AM, Chételat G, Citron M, DeVos SL, Diaz K, Feldman HH, Frost B, Goate AM, Gold M, Hyman B, Johnson K, Karch CM, Kerwin DR, Koroshetz WJ, Litvan I, Morris HR, Mummery CJ, Mutamba J, Patterson MC, Quiroz YT, Rabinovici GD, Rommel A, Shulman MB, Toledo-Sherman LM, Weninger S, Wildsmith KR, Worley SL, Carrillo MC. Current directions in tau research: Highlights from Tau 2020. Alzheimers Dement. 2021 Sep 28; doi: 10.1002/alz.12452. Epub 2021 Sep 28. PMID: 34581500.
Copy Download .nbib Format: NLM
Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study.

JAMA neurology

, Feigin VL, Vos T, Alahdab F, Amit AML, Bärnighausen TW, Beghi E, Beheshti M, Chavan PP, Criqui MH, Desai R, Dhamminda Dharmaratne S, Dorsey ER, Wilder Eagan A, Elgendy IY, Filip I, Giampaoli S, Giussani G, Hafezi-Nejad N, Hole MK, Ikeda T, Owens Johnson C, Kalani R, Khatab K, Khubchandani J, Kim D, Koroshetz WJ, Krishnamoorthy V, Krishnamurthi RV, Liu X, Lo WD, Logroscino G, Mensah GA, Miller TR, Mohammed S, Mokdad AH, Moradi-Lakeh M, Morrison SD, Shivamurthy VKN, Naghavi M, Nichols E, Norrving B, Odell CM, Pupillo E, Radfar A, Roth GA, Shafieesabet A, Sheikh A, Sheikhbahaei S, Shin JI, Singh JA, Steiner TJ, Stovner LJ, Wallin MT, Weiss J, Wu C, Zunt JR, Adelson JD, Murray CJL.
PMID: 33136137
JAMA Neurol. 2021 Feb 01;78(2):165-176. doi: 10.1001/jamaneurol.2020.4152.

IMPORTANCE: Accurate and up-to-date estimates on incidence, prevalence, mortality, and disability-adjusted life-years (burden) of neurological disorders are the backbone of evidence-based health care planning and resource allocation for these disorders. It appears that no such estimates have been reported...

Cite
, Feigin VL, Vos T, et al. Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study. JAMA Neurol. 2021;78(2):165-176doi: 10.1001/jamaneurol.2020.4152.
, Feigin, V. L., Vos, T., Alahdab, F., Amit, A. M. L., Bärnighausen, T. W., Beghi, E., Beheshti, M., Chavan, P. P., Criqui, M. H., Desai, R., Dhamminda Dharmaratne, S., Dorsey, E. R., Wilder Eagan, A., Elgendy, I. Y., Filip, I., Giampaoli, S., Giussani, G., Hafezi-Nejad, N., Hole, M. K., Ikeda, T., Owens Johnson, C., Kalani, R., Khatab, K., Khubchandani, J., Kim, D., Koroshetz, W. J., Krishnamoorthy, V., Krishnamurthi, R. V., Liu, X., Lo, W. D., Logroscino, G., Mensah, G. A., Miller, T. R., Mohammed, S., Mokdad, A. H., Moradi-Lakeh, M., Morrison, S. D., Shivamurthy, V. K. N., Naghavi, M., Nichols, E., Norrving, B., Odell, C. M., Pupillo, E., Radfar, A., Roth, G. A., Shafieesabet, A., Sheikh, A., Sheikhbahaei, S., Shin, J. I., Singh, J. A., Steiner, T. J., Stovner, L. J., Wallin, M. T., Weiss, J., Wu, C., Zunt, J. R., Adelson, J. D., & Murray, C. J. L. (2021). Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study. JAMA neurology, 78(2), 165-176. https://doi.org/10.1001/jamaneurol.2020.4152
, et al. "Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study." JAMA neurology vol. 78,2 (2021): 165-176. doi: https://doi.org/10.1001/jamaneurol.2020.4152
, Feigin VL, Vos T, Alahdab F, Amit AML, Bärnighausen TW, Beghi E, Beheshti M, Chavan PP, Criqui MH, Desai R, Dhamminda Dharmaratne S, Dorsey ER, Wilder Eagan A, Elgendy IY, Filip I, Giampaoli S, Giussani G, Hafezi-Nejad N, Hole MK, Ikeda T, Owens Johnson C, Kalani R, Khatab K, Khubchandani J, Kim D, Koroshetz WJ, Krishnamoorthy V, Krishnamurthi RV, Liu X, Lo WD, Logroscino G, Mensah GA, Miller TR, Mohammed S, Mokdad AH, Moradi-Lakeh M, Morrison SD, Shivamurthy VKN, Naghavi M, Nichols E, Norrving B, Odell CM, Pupillo E, Radfar A, Roth GA, Shafieesabet A, Sheikh A, Sheikhbahaei S, Shin JI, Singh JA, Steiner TJ, Stovner LJ, Wallin MT, Weiss J, Wu C, Zunt JR, Adelson JD, Murray CJL. Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study. JAMA Neurol. 2021 Feb 01;78(2):165-176. doi: 10.1001/jamaneurol.2020.4152. PMID: 33136137; PMCID: PMC7607495.
Copy Download .nbib Format: NLM
Transient Ischemic Attack and Secondary Stroke.

Current treatment options in neurology

McDonald CT, Koroshetz WJ.
PMID: 11096758
Curr Treat Options Neurol. 2000 Jul;2(4):329-342. doi: 10.1007/s11940-000-0050-x.

Transient ischemic attack (TIA) is a clinical syndrome that has been shown to be a major risk factor for stroke. Patients with transient neurologic deficits of sudden onset that last less than 24 hours require prompt medical and neurologic...

Cite
McDonald CT, Koroshetz WJ. Transient Ischemic Attack and Secondary Stroke. Curr Treat Options Neurol. 2000;2(4):329-342doi: 10.1007/s11940-000-0050-x.
McDonald, C. T., & Koroshetz, W. J. (2000). Transient Ischemic Attack and Secondary Stroke. Current treatment options in neurology, 2(4), 329-342. https://doi.org/10.1007/s11940-000-0050-x
McDonald, and Koroshetz. "Transient Ischemic Attack and Secondary Stroke." Current treatment options in neurology vol. 2,4 (2000): 329-342. doi: https://doi.org/10.1007/s11940-000-0050-x
McDonald CT, Koroshetz WJ. Transient Ischemic Attack and Secondary Stroke. Curr Treat Options Neurol. 2000 Jul;2(4):329-342. doi: 10.1007/s11940-000-0050-x. PMID: 11096758.
Copy Download .nbib Format: NLM
Transient ischemic attack: are there different types or classes? Risk of stroke and treatment options.

Current treatment options in cardiovascular medicine

Ay H, Koroshetz WJ.
PMID: 16635438
Curr Treat Options Cardiovasc Med. 2006 May;8(3):193-200. doi: 10.1007/s11936-006-0012-z.

Recent advances in neuroimaging have revolutionized the evaluation of the clinical syndrome of transient ischemic attack (TIA). Diffusion-weighted imaging demonstrates microinfarctions (< 1 cm(3)) in approximately 50% of patients with TIA, establishing that not all clinically transient spells are...

Cite
Ay H, Koroshetz WJ. Transient ischemic attack: are there different types or classes? Risk of stroke and treatment options. Curr Treat Options Cardiovasc Med. 2006;8(3):193-200doi: 10.1007/s11936-006-0012-z.
Ay, H., & Koroshetz, W. J. (2006). Transient ischemic attack: are there different types or classes? Risk of stroke and treatment options. Current treatment options in cardiovascular medicine, 8(3), 193-200. https://doi.org/10.1007/s11936-006-0012-z
Ay, Hakan, and Koroshetz, Walter J. "Transient ischemic attack: are there different types or classes? Risk of stroke and treatment options." Current treatment options in cardiovascular medicine vol. 8,3 (2006): 193-200. doi: https://doi.org/10.1007/s11936-006-0012-z
Ay H, Koroshetz WJ. Transient ischemic attack: are there different types or classes? Risk of stroke and treatment options. Curr Treat Options Cardiovasc Med. 2006 May;8(3):193-200. doi: 10.1007/s11936-006-0012-z. PMID: 16635438.
Copy Download .nbib Format: NLM
NINDS launches network to develop treatments for ultra-rare neurological diseases.

Nature biotechnology

Schor NF, Tamiz AP, Koroshetz WJ, Broome AM.
PMID: 34737446
Nat Biotechnol. 2021 Dec;39(12):1497-1499. doi: 10.1038/s41587-021-01125-w.

No abstract available.

Cite
Schor NF, Tamiz AP, Koroshetz WJ. NINDS launches network to develop treatments for ultra-rare neurological diseases. Nat Biotechnol. 2021;39(12):1497-1499doi: 10.1038/s41587-021-01125-w.
Schor, N. F., Tamiz, A. P., Koroshetz, W. J., & Broome, A. M. (2021). NINDS launches network to develop treatments for ultra-rare neurological diseases. Nature biotechnology, 39(12), 1497-1499. https://doi.org/10.1038/s41587-021-01125-w
Schor, Nina F, et al. "NINDS launches network to develop treatments for ultra-rare neurological diseases." Nature biotechnology vol. 39,12 (2021): 1497-1499. doi: https://doi.org/10.1038/s41587-021-01125-w
Schor NF, Tamiz AP, Koroshetz WJ, Broome AM. NINDS launches network to develop treatments for ultra-rare neurological diseases. Nat Biotechnol. 2021 Dec;39(12):1497-1499. doi: 10.1038/s41587-021-01125-w. PMID: 34737446.
Copy Download .nbib Format: NLM
Bridging the Gap in Neurotherapeutic Discovery and Development: The Role of the National Institute of Neurological Disorders and Stroke in Translational Neuroscience.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Mott M, Koroshetz W.
PMID: 26081907
Neurotherapeutics. 2015 Jul;12(3):651-4. doi: 10.1007/s13311-015-0366-6.

The mission of the National Institute of Neurological Disorders and Stroke (NINDS) is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease. NINDS supports early- and...

Cite
Mott M, Koroshetz W. Bridging the Gap in Neurotherapeutic Discovery and Development: The Role of the National Institute of Neurological Disorders and Stroke in Translational Neuroscience. Neurotherapeutics. 2015;12(3):651-4doi: 10.1007/s13311-015-0366-6.
Mott, M., & Koroshetz, W. (2015). Bridging the Gap in Neurotherapeutic Discovery and Development: The Role of the National Institute of Neurological Disorders and Stroke in Translational Neuroscience. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 12(3), 651-4. https://doi.org/10.1007/s13311-015-0366-6
Mott, Meghan, and Koroshetz, Walter. "Bridging the Gap in Neurotherapeutic Discovery and Development: The Role of the National Institute of Neurological Disorders and Stroke in Translational Neuroscience." Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics vol. 12,3 (2015): 651-4. doi: https://doi.org/10.1007/s13311-015-0366-6
Mott M, Koroshetz W. Bridging the Gap in Neurotherapeutic Discovery and Development: The Role of the National Institute of Neurological Disorders and Stroke in Translational Neuroscience. Neurotherapeutics. 2015 Jul;12(3):651-4. doi: 10.1007/s13311-015-0366-6. PMID: 26081907; PMCID: PMC4489962.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 18 entries